Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study

Fig. 3

Representative case with different expression of PD-L1 protein and DDR mutation of each patient. a Positive PD-L1 (TAP ≥ 1%) in case 11, 23, and 30; negative PD-L1 in case 18 (TAP < 1%); Tumor area positivity (TAP) ≥ 1% was defined as positive. Proportion of tumor and/or immune cells with PD-L1 staining at any intensity. b. DDR-related genetic alternations and pathways identified by WES analysis in 30 patients. Red arrow refers to representative cases (case 23, 30, with multi-DDR mutation, and case 11, 18 without DDR mutation)

Back to article page